Halozyme Therapeutics (HALO) is the Chart of the Day. The biopharmaceutical stock is up 58.46% in the last 6 months and has a Trend Spotter buy signal.
Article:
The Chart of the Day is Halozyme Therapeutics (HALO). I found the stock near the top of the New High List when sorted for frequency. The stock has both a Trend Spotter buy and 80% technical buy signals.
It is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.
Barchart technical indicators:
- 80% Barchart technical buy signals
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 15 new highs and up 37.90% in the last month
- Relative strength Index 72.70%
- Barchart computes a technical support level at 8.50
- Recenlty traded at 9.28 with a 50 day moving average of 7.87
Fundamental factors:
- $1.05 billion
- Revenue projected to increase 16.20% this year and another 33.50% next year
- Earnings estimated to shrink 22.90% this year but grow again by 32.00% next year
- Wall Street analysts issued 1 strong buy, 3 buy, 3 hold and a sell recommendation
- Financial Strength B+
This is a technical momentum sock so watch the 50 day moving averages for weakness.
No comments:
Post a Comment